This review focuses on activating NKG2D receptor, its ligands, their regulation, and on the role of their polymorphism in AML patients and dependency of the polymorphism of NKG2D and its ligands on HSCT outcome. This evidence concerns the gene KLRK1 and acute myeloid leukemia.